Title: The Controversy Surrounding the Potential Use of Magic Mushrooms in NHS Depression Treatment

Larissa Hope asserts that psilocybin, the psychoactive compound found in magic mushrooms, played a pivotal role in overcoming a severe mental health struggle. At 17, as she began her acting career with a role in the television series Skins, sudden fame triggered long-suppressed trauma. While traditional antidepressants failed to help her, a clinically supervised dose of psilocybin proved transformative. “When I experienced it, I burst out crying,” Hope recalls. “It was the first time in my life I had ever felt a sense of belonging and safety in my body I kept saying, 'I'm home, I'm home'.” Nearly two decades later, Hope credits this experience, combined with therapy, for helping her overcome suicidal ideation.

However, not all accounts are positive. Jules Evans, a university researcher, describes a profoundly negative reaction to his first LSD experience at age 18, which was taken recreationally. He entered a “deluded” state, believing everyone was criticizing and judging him, and fearing he had permanently damaged his mind. “It was the most terrifying experience of my life,” he says. Evans now directs the Challenging Psychedelic Experiences Project, supporting those who suffer adverse effects after using psychedelics. He reveals that years after his trip, he continued to struggle with social anxiety and panic attacks, eventually receiving a diagnosis of post-traumatic stress disorder (PTSD).

These contrasting narratives highlight the central dilemma facing medical professionals, regulators, and politicians: should physicians be permitted to prescribe treatments involving magic mushrooms and other potentially therapeutic psychedelic substances?

This question has gained urgency following recent studies suggesting psychedelics may aid in treating depression, obsessive-compulsive disorder, PTSD, trauma, and addictions related to alcohol and gambling. Currently, the use of psychedelic medicine remains illegal except within authorized clinical trials or research settings. Since 2022, over 20 trials have investigated various psychedelic medicines for conditions including depression, PTSD, and addiction. While many studies indicate therapeutic benefits, several have produced mixed or inconclusive results, with only a few showing no clear advantage on primary metrics.

Awaiting publication later this year are the results from one of the largest clinical trials on psilocybin, conducted by UK biotech firm Compass Pathways. The UK’s medicines regulator is reviewing this data to determine if current strict restrictions can be relaxed to permit the use of psychedelic medicine outside of research contexts.

Professor Oliver Howes, chair of the Royal College of Psychiatrists’ Psychopharmacology Committee, expresses optimism regarding psychedelics as a potential new treatment for psychiatric disorders within the NHS. “One of the key messages is that this is something we desperately need - more treatments and better treatments for mental health disorders… These treatments are really interesting because they've shown promise in these small-scale studies… and have the potential to work quicker.” Nevertheless, he urges caution, stressing the importance of robust evidence before overstating the benefits.

Other experts have also called for restraint. A September 2025 report by the Royal College of Psychiatrists highlighted the potential risks associated with psychedelics, while doctors emphasize that using these drugs is not only unlawful but can also be dangerous.

Faster Acting, Fewer Side Effects?

The use of drugs for recreational or ritualistic purposes is as ancient as civilization itself, with magic mushrooms, opium, and cannabis having long histories of use. By the 1960s and 1970s, LSD, also

Source: BBC News Generated at: 2026-01-02 15:47:15 UTC